

# PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC



P. BLANCO GARCIA<sup>1</sup>, M. ANTON MARTINEZ<sup>1</sup>, A. FIJÓ PRIETO<sup>1</sup>, M.T. SÁNCHEZ SÁNCHEZ<sup>1</sup>  
<sup>1</sup>HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID, HOSPITAL PHARMACY, VALLADOLID, SPAIN.

## BACKGROUND AND IMPORTANCE

- ✓ The impact of Covid-19 and its influence in the management of hospitalized patients has been indisputable. Many publications present combinations of different antimicrobials to treat the patients infections, and the Liposomal Amphotericin B (Amb-L) is an example of one of the most prescribed.



## AIM AND OBJECTIVES



- ✓ To compare the prescription and indication of Amb-L in a tertiary care hospital before and during the Covid-19 pandemic.

## MATERIAL AND METHODS

- ✓ Descriptive study of patients prescribed AmB-L
- ✓ Observational
- ✓ Retrospective



March 2020 to March 2021

## RESULTS

March 2020 to March 2021

18/56 40/56






Median age: 63,5 years

March 2021

December 2020

July 2020

Most prescriptions months



-**TARGET TREATMENT** for *C. albicans* and *C. glabrata* (16/26), *A. fumigatus* (6/26) and *Mucor* (4/26).

-**Concomitant therapy**: ANIDULAFUNGIN AND ISAVUCONAZOLE.

-**Dosage**: 5 mg/kg/day for 7 days [IQR 4-17,5].

-**EMPIRICAL TREATMENT** 10/17 patients for febrile neutropenia.

-**Concomitant therapy**: POSACONAZOLE AND ITRACONAZOLE.

-**Dosage**: 3,3mg/kg/day for 9 days [IQR 6-16].

	YEAR BEFORE PANDEMIC	COVID-19 PANDEMIC PERIOD
Total number of patients	17	56
Women	5	18
Men	17	38
Median age	53 years [IQR: 38,2-59,1]	63,5 years [IQR: 49,5-71,25]



## CONCLUSION AND RELEVANCE

- ✓ The prescription **is tripled** during the observed period in all the described fields.
- ✓ **Critical patients profile**: unstable, risk factors and with higher doses of AmB-L.
- ✓ It is **necessary to optimize** the use of Amb-L to guarantee efficiency and pharmaceutical spending.

